Market Overview

Enanta Pharmaceuticals Announces Additional Data from AbbVie's M13-393 Study to be Presented at Liver Meeting

Mid-Morning Market Update: Markets Open Higher; VeriFone Issues Weak Outlook
Earnings Scheduled For November 20, 2017

Enanta Pharmaceuticals (NASDAQ: ENTA) today announced that
additional data from AbbVie's M13-393 (NYSE: ABBV) study, referred to as PEARL-I,
will be presented in an oral presentation at 5:15 p.m. ET today at The
Liver Meeting, the 64th Annual Meeting of the American
Association for the Study of Liver Diseases (AASLD) in Washington, D.C.

In PEARL-I, SVR12 rates of 95% (40/42) in hepatitis C (HCV) GT-1b
treatment-naïve patients and 90% (36/40) among prior null responders
will be presented in this intent-to-treat analysis. Two patients in the
treatment-naive arm did not achieve SVR12 due to loss to follow up. In

See full press release

Posted-In: News Guidance FDA Global


Related Articles (ABBV)

View Comments and Join the Discussion!